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Objective  To investigate the usefulness of bioimpedance measurement  for predicting the treatment outcome in 
breast cancer related lymphedema (BCRL) patients.
Method  Unilateral BCRL patients who received complex decongestive therapy (CDT) for 2 weeks (5 days per 
week) were enrolled in this study. We measured the ratio of extracellular fl  uid (ECF) volume by using bioelectrical 
impedance spectroscopy (BIS), and single frequency bioimpedance analysis (SFBIA) at a 5 kHz frequency before 
treatment. Arm circumferences were measured at 10 cm above and below the elbow before and after treatment. 
We also investigated whether there is correlation between ECF ratio and SFBIA ratio with the change of arm 
circumference after CDT.
Results  A total of 73 patients were enrolled in this study. Th   e higher ECF ratio was signifi  cantly correlated with 
higher reduction of arm circumference at both above and below the elbow after treatment, but the higher SFBIA 
ratio was correlated only with the higher reduction of arm circumference below the elbow.
Conclusion  Th   ese results show that ECF volume measurements and SFBIA before treatment are useful tools for 
predicting the outcome of patients with lymphedema. We concluded that ECF volume measure can be used as a 
screening tool for predicting treatment outcome of BCRL patients.
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INTRODUCTION
  Lymphedema is a chronic disease of the lymphatic 
system and is characterized by interstitial accumulation 
of protein, fluid, and subsequent inflammation and 
fi  brosis.
1 Primary lymphedema is a rare condition in the 
general population and occurs secondary to congenital 
anatomic abnormalities of the lymphatic system, such 
as lymphatic dysplasia or lymphatic valve dysfunction. 
Secondary lymphedema is a relatively common condition 
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after treatment of malignancy, especially in breast cancer 
patients who were treated with axillary lymph nodes 
dissection and/or radiation therapy on axillary lymph 
nodes. Secondary lymphedema can cause pain, swelling, 
limited joint range of motion, and infections such as 
cellulitis on an aff  ected region.
2 Reports concerning the 
incidence of secondary lymphedema after breast cancer 
treatment range from 2% to 83%, but the incidence is 
generally accepted as being -30% in patients treated with 
axillary surgery and radiotherapy. Th   e incidence is higher 
in patients with axillary lymph node dissection than in 
those with sentinel lymph node biopsy, and it is known to 
occur within 1-2 years after treatment of breast cancer.
3-7
  The International Society of Lymphology classified 
lymphedema on a scale of 0 to 3 using the following para-
meters: Stage 0 refers to a latent or subclinical condition 
where swelling is not evident despite impaired lymphatic 
transformation. Stage I is a condition during which 
protein rich fluid accumulates and the edema subsides 
with limb elevation. In stage II, tissue fibrosis develops 
and limb elevation alone rarely reduces tissue edema. 
Finally, tissue edema and fibrosis are aggravated and 
trophic skin changes are developed in stage III.
1 Because 
prognosis is worse and more complications occur as 
disease progresses, early treatment and maintenance are 
important.
3,4,8-10
  The severity of lymphedema can be evaluated by 
measuring limb circumference, volume, tissue tono-
metry, or water displacement method. Although these 
methods are simple and convenient, they cannot des-
cribe the tissue composition of affected limbs. On the 
other hand, Bioimpedance measurement is a recently 
developed method and it attempts to calculate the 
amount of body fluid by measuring impedance to elec-
trical current that passes through a body segment. This 
method can be used on limbs with lymphedema; to 
determine whether the affected limb consists mainly 
of fluid or other components.
11 Several researchers 
studied the usefulness of bioimpedance in patients with 
lymphedema, but those reports discussed diagnosis 
or evaluation of severity,
2,7,12,13 and there was no report 
concerning a bioimpedance measurement being used 
to predict prognosis after treatment of lymphedema. 
We suggested the prognosis of lymphedema would be 
different by the tissue composition, and we attempted 
to predict prognosis of lymphedema by assessing tissue 
composition by measuring bioimpedance.
MATERIALS AND METHODS
Subjects
  Patients who visited the Asan Medical Center Lym-
phedema Clinic from April, 2010 to October, 2010 were 
considered for entry into the trial. Th  e  following  criteria 
had to be met before a patient was enrolled into the trial: 
age of ≥18 years, female gender only, history of surgery 
and/or radiotherapy and/or chemotherapy, diagnosis 
of lymphedema by lymphoscintigraphy, circumference 
difference of both arms >2 cm at 10 cm either below or 
above elbow. Participants were excluded on the following 
criteria: presence of certain comorbidities (current me-
ta  stasis, active infectious condition, such as cellulitis 
of affected arm), history of trauma, or surgery to the 
aff  ected arm.
Treatment of lymphedema
  Complex decongestive therapy (CDT) was conducted 
on patients for 30 minutes a day, for 10 days (5 days per 
week). CDT was composed of manual lymphatic drain-
age, compression bandaging, exercises to enhance lym-
phatic drainage, and patient education. During treatment 
periods, CDT was performed by same physical therapist 
for each patient. 
Evaluation
  Prior to CDT, we evaluated the calculated extracellular 
fl  uid (ECF) and single frequency bioimpedance analysis 
(SFBIA) value at 5 kHz for both upper extremities with 
Inbody 720
® (Biospace, Seoul, South Korea). Circum-
ferences of both arms 10 cm at above and below the 
elbow were also checked before and after 2 weeks of the 
CDT period.
  The ECF ratios of the unaffected to affected side and 
aff  ected to unaff  ected side ratio of SFBIA value at 5 kHz 
were calculated and we investigated whether there was a 
correlation between these values and arm circumference 
changes after 2 weeks of CDT. After evaluation of bio-
impedance values and arm circumferences changes, we 
investigated whether these bioimpedance values can 
predict the extent of improvement. Prediction of Treatment Outcome with Bioimpedance Measurements in BCRL Patients
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Statistical analysis
  All statistical analyses were performed using SPSS, 
version 18.0. Data evaluated in our study did not show 
a normal distribution, and we performed a Spearman’s 
correlation coefficient to investigate the correlation of 
bioimpedance values and differences between both 
arm circumferences, and arm circumference changes 
after treatment. A partial correlation coeffi   cient was also 
Table 1. Patient Demographic Data 
Factors Values
Sex (male : female) 0 : 73
Age (years) 49.4±9.0
Lesion side (right : left) 37 : 36
Body mass index (kg/m
2) 24.0±2.9
Disease duration (months)   16.1±22.8




   Aff  ected arm   0.34±0.01
   Unaff  ected arm   0.33±0.01
   Ratio of aff  ected to unaff  ected arm   1.02±0.02
SFBIA at 5 kHz
   Aff  ected arm 392.93±51.31
   Unaff  ected arm 335.87±67.50
   Ratio of unaff  ected to aff  ected arm   1.17±0.18
Arm circumference change above
  the elbow level
  1.3±0.8
Arm circumference change below
  the elbow level
 1.5±0.8
ECF: Extracellular fl  uid, SFBIA: Single frequency bioim-
pedance analysis
Fig. 1. Relationship of bioimpedance value with diff  erences of bilateral arm circumference above (A, C) and below the elbow (B, 
D) (*p<0.05, 
†p<0.01).  ECF: Extracellular fl  uid, SFBIA: single frequency bioimpedance analysis.Leesuk Kim, et al.
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calculated to adjust for age, body mass index (BMI), 
disease duration, because these factors can affect the 
result of this study. Statistical signifi  cance was defi  ned as 
a p-value<0.05.
RESULTS
Demographic data of patients
  A total of 73 BCRL patients were enrolled in our study.   
Their mean age was 49.4±9.0 years and mean disease 
duration was 16.1±22.8 months (Table 1).
Values of clinical data
  Calculated ECF, SFBIA values at 5 kHz, and their ra-
tios before treatment of lymphedema, and arm circum-
ferences changes after CDT are presented in Table 2. 
Before CDT, higher calculated ECF and SFBIA ratios were 
significantly correlated with higher differences of arm 
circumferences between both sides (Fig. 1). 
Correlation between bioimpedance values and arm 
circumference changes
  Because calculated ECF ratios were higher, arm circum-
ference changes at 10 cm above and below the elbow 
were higher (Fig. 2-A, B), and the same results were 
shown after adjustment for age, BMI, and disease dura-
tion (Table 3). Higher SFBIA ratio was significantly cor-
related with arm circumference changes at 10 cm both 
above and below elbow (Fig. 2-C, D), but the correlation 
of SFBIA and arm circumference change at 10 cm above 
the elbow was not significant after adjustment of age, 
BMI, and disease duration (Table 3).
Fig. 2. Correlation of bioimpedance value and change of arm circumferences above (A, C) and below elbow (B, D)  (*p<0.05, 
†p<0.01). ECF: Extracellular fl  uid, SFBIA: single frequency bioimpedance analysis.Prediction of Treatment Outcome with Bioimpedance Measurements in BCRL Patients
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DISCUSSION
  Th   e primary object of this study was to investigate whe-
ther bioimpedance measurements could help in pre-
dicting the treatment outcome in BCRL patients. There 
was a significant difference between bioimpedance va-
lues of an affected arm and those of an unaffected arm 
in our study, and this result is in agreement with results 
from previous studies.
2,12-14 
  Protein, fl  uid, fi  brotic and fatty tissues are accumulated 
in extremities with lymphedema. Composition of an ex-
tre  mity is infl  uenced by stages and the treatment out  come 
differs by composition of the extremity. In other words, 
when there is more fl  uid than fi  brotic or fatty tissue, the 
treatment outcome will be better. We hypothesized that 
calculating the extent of fluid in upper extremities with 
lymphedema would predict the treatment outcome of 
BCRL patients, and we observed a larger arm circum-
ference reduction in patients with more fl  uid in an upper 
extremity.
  Bioimpedance analysis measures body response to 
applied electrical current and calculates the body fluid 
volume. This technique is relatively new and one of 
several methods available to differentiate extracellular 
fluid from total limb volume. There are reports that 
measurement of bioimpedance is useful for early diag-
nosis and assessing severity of lymphedema.
14,15 Current 
flow in biological tissue is frequency dependent. At 
higher frequencies, reactance of cellular membranes 
decreases, and electrical current can pass through both 
the extra- and intracellular fluid. However, electrical 
cur  rent at zero frequency can pass only extracellular 
fluid at zero frequencies, because reactance from cel-
lular membranes acts as insulator to electrical current. 
Therefore, a bioimpedance measurement at zero fre-
quency is useful in evaluating lymphedema, when fl  uid 
accumulates mainly in the extracellular space. Bio-
impedance measurements at zero frequency are currently 
impossible to obtain. There are alternative methods for 
overcoming limitations of this technique. One method 
is bioelectrical impedance spectroscopy (BIS), which 
measures impedance at many frequencies and calculates 
the impedance at zero frequency. The other method is 
single frequency bioimpedance analysis (SFBIA), which 
measures impedance at a single, low frequency that is 
close to zero.
11 In our study, we defined the calculated 
ECF ratio as a ratio of the aff  ected to the unaff  ected side, 
and SFBIA ratio as a ratio of the unaff  ected to the aff  ected 
side. A lower value of SFBIA at 5 kHz suggests that there 
is fluid in extracellular space, and higher ratios of both 
calculated ECF and SFBIA suggest that there is more ECF. 
   Warren et al. reported that BIS values of an aff  ected arm 
in BCRL patients were significantly higher than those 
of healthy control subjects, thus they suggested BIS as a 
useful technique in diagnosing lymphedema.
2 According 
to Cornish et al., patients in which BIS values were > 3 
standard deviations from those of healthy controls were 
diagnosed as having lymphedema after 10 months.
13 
Ward et al. reported that total arm volume measured by 
perometry was highly correlated with arm fl  uid volumes 
predicted by BIS, and the correlation of total arm volume 
with ECF volume was higher than that of total arm vo-
lume with ICF volume.
12 As these studies show, BIS is an 
accurate technique for assessing lymphedema. SFBIA 
is known to be less accurate than BIS, but the clinical 
usefulness of SFBIA has been reported by investigators. 
York et al. reported the high correlation of SFBIA and 
BIS and they concluded that SFBIA is a simple accurate 
alternative to BIS for the clinical assessment of unilateral 
lymphedema.
15
  Many studies have applied bioimpedance measure-
ments to lymphedema patients, but they concerned early 
diagnosis and assessing severity of lymphedema. To the 
best of our knowledge, no prior study has conducted 
to predict the treatment outcome using bioimpedance 
measurements, and our study is the first to investigate 
whether a bioimpedance measurement is useful for 
predicting treatment outcome. Arm circumference 
and volume measurements have been frequently used 
to assess severity of lymphedema, but these methods 
Table 3. Correlation Efficiency between Bioimpedance 
Value and Arm Circumference Change after Adjustment 




Above elbow level 0.526
† 0.216
Below elbow level 0.338
†   0.296*
BMI: Body mass index, ECF: Extracellular fluid, SFBIA: 
Single frequency bioimpedance analysis
*p<0.05, 
†p<0.01Leesuk Kim, et al.
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cannot determine the composition of an affected arm 
and thus it was difficult to predict treatment outcome 
with these methods. We attempted to predict treatment 
outcome by measurement of bioimpedance. In our pre-
sent study, higher ratios of calculated ECF and SFBIA 
were signifi  cantly correlated with diff  erences of both arm 
circumferences and changes of affected arm circum-
ference. However, SFBIA ratio was not signifi  cantly corre-
lated with arm circumference change at 10 cm above 
the elbow after adjustment for age, BMI, and disease 
duration. Although there were significant correlations 
between ratios of bioimpedance values and clinical data, 
calculated ECF and SFBIA ratios did not show a strong 
correlation with diff  erences of arms circumference (Fig. 
1), and arm circumference changes (Table 3). 
  In our study, difference and change of arm circum-
ference were correlated with calculated ECF than SFBIA. 
And these results are in agreement with results from 
pre vious  study.
15  Th   e SFBIA ratio at 5 kHz predicted the 
arm circumference change at below the elbow level, but 
was not signifi  cantly correlated with arm circumference 
change above the elbow level. This may be because 
the severity of lymphedema can be different in regions 
above and below the elbow, but this technique cannot 
separately measure fluid volumes below and above the 
elbow level. 
  In our present study, we suggest that measurement of 
bioimpedance can help in predicting treatment out-
come by estimating fluid volume of the affected arm in 
lymphedema patients. However, correlation coeffi   cients 
of bioimpedance values and clinical data indicate that 
bioimpedance measure is not very accurate for predicting 
treatment outcome. Th   is means that while bioimpedance 
measurements are useful tools for assessing severity and 
predicting treatment outcome, it is better to interpret 
the results of bioimpedance measure comparising with 
evaluation tools, such as arm circumference and volume 
measure, water displacement method, and lymph  scin-
tigraphy. BIS is a more accurate method than SFBIA, but 
the BIS device requires a large amount of space. On the 
other hand, the SFBIA device is simple and small, so it 
can be easily used in clinical situations. Physicians need 
to understand the advantages and disadvantages of these 
devices and appropriately apply them to patients. 
  Th   ere are some limitations in our study. First, our sam-
ple size was small; however, sample sizes of previous 
studies on bioimpedance measurement were smaller 
than that of our study
2,7,12,13,15 and more reliable results 
would be expected if more patients are enrolled. Second, 
except for the study of Carati et al.
7, devices used in other 
studies were diff  erent from that used in our study. Th  ird, 
our device could not directly measure ECF volume, but 
could only calculate the ratio of ECF to total arm volume. 
If we could directly measure ECF volume, more accurate 
results could be expected. Th   erefore, further studies with 
devices that directly measure ECF volume are needed.   
Finally, our study considered the disease duration, but 
we did not consider the stage of lymphedema. Because 
treatment outcome diff  ers with diff  erent disease stage, if 
we analyzed our results relative to disease stage, we could 
obtain more accurate results.
CONCLUSION
  In the present study, bioimpedance values measured 
by BIS and SFBIA were signifi  cantly correlated with arm 
circumferences changes, and it appears that BIS is more 
accurate than SFBIA. Th   us, estimating ECF volume with 
bioimpedance measurement may be a useful modality 
for assessing severity and predicting treatment outcome 
in lymphedema patients. Further studies concerning the 
accuracy and usefulness of bioimpedance measure will 
be needed.
REFERENCES
1. W  arren AG, Brorson H, Borud LJ, Slavin SA. Lymph-
edema: a comprehensive review. Ann Plast Surg 2007; 
59: 464-472
2. Warren AG, Janz BA, Slavin SA, Borud LJ. The use of 
bioimpedance analysis to evaluate lymphedema. Ann 
Plast Surg 2007; 58: 541-543
3. Hayes SC, Janda M, Cornish B, Battistutta D, Newman 
B. Lymphedema after breast cancer: incidence, risk 
factors, and effect on upper body function. J Clin 
Oncol 2008; 26: 3536-3542
4. Sener SF, Winchester DJ, Martz CH, Feldman JL, 
Cava  naugh JA, Winchester DP, Weigel B, Bonnefoi 
K, Kirby K, Morehead C. Lymphedema after sentinel 
lymphadenectomy for breast carcinoma. Cancer 2001; 
92: 748-752
5. Meneses KD, McNees MP. Upper extremity lymphe-Prediction of Treatment Outcome with Bioimpedance Measurements in BCRL Patients
693 www.e-arm.org
dema after treatment for breast cancer: a review of the 
literature. Ostomy Wound Manage 2007; 53: 16-29
6. Erickson VS, Pearson ML, Ganz PA, Adams J, Kahn KL. 
Arm edema in breast cancer patients. J Natl Cancer 
Inst 2001; 93: 96-111
7. Carati CJ, Anderson SN, Gannon BJ, Piller NB. Treat-
ment of postmastectomy lymphedema with low-level 
laser therapy: a double blind, placebo-controlled trial. 
Cancer 2003; 98: 1114-1122
8. Petrek JA, Heelan MC. Incidence of breast carcinoma-
related lymphedema. Cancer 1998; 83: 2776-2781
9. Rietman JS, Dijkstra PU, Geertzen JH, Baas P, de Vries 
J, Dolsma WV, Groothoff   JW, Eisma WH, Hoekstra HJ. 
Treatment-related upper limb morbidity 1 year after 
sentinel lymph node biopsy or axillary lymph node 
dissection for stage I or II breast cancer. Ann Surg 
Oncol 2004; 11: 1018-1024
10.  Szuba A, Rockson SG. Lymphedema: classification, 
diagnosis and therapy. Vasc Med 1998; 3: 145-156
11.  Cornish B. Bioimpedance analysis: scientific back-
ground. Lymphat Res Biol 2006; 4: 47-50
12.   Ward LC, Czerniec S, Kilbreath SL. Quantitative bio-
im  pedance spectroscopy for the assessment of lymph-
oedema. Breast Cancer Res Treat 2009; 117: 541-547
13.   Cornish BH, Chapman M, Hirst C, Mirolo B, Bunce IH, 
Ward LC, Th   omas BJ. Early diagnosis of lymphedema 
using multiple frequency bioimpedance. Lymphology 
2001; 34: 2-11
14. Ward LC. Bioelectrical impedance analysis: pro  ven 
utility in lymphedema risk assessment and thera  peu-
tic monitoring. Lymphat Res Biol 2006; 4: 51-56
15.   York SL, Ward LC, Czerniec S, Lee MJ, Refshauge KM, 
Kilbreath SL. Single frequency versus bioimpedance 
spectroscopy for the assessment of lymphedema. 
Breast Cancer Res Treat 2009; 117: 177-182